Evotec opens new state-of-the-art biology facility on Dorothy Crowfoot Hodgkin Campus


Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park. Evotec has had a presence in Abingdon since the Company’s acquisition of Oxford Asymmetry International plc (“OAI”) in 2000 and today is one of the largest occupiers at Milton Park.

Evotec has developed B95 to accommodate new state-of-the-art biology laboratories, a range of collaborative workspaces and meeting rooms as well as a restaurant for employees. The B95 facility was designed with a particular focus on sustainability, and incorporates air source heat pumps, a demand-based laboratory ventilation system, as well as low energy lighting and appliances. These measures will support Evotec in achieving the company’s carbon neutral targets.

George Freeman MP, Minister of State at the Department for Science, Innovation and Technology said: “The opening of these state-of-the-art new labs is further evidence of the strength of the UK’s £ 94 bn life sciences sector, which adds to the 280,000 jobs the industry already supports nationwide and attracts private investment into local economies. The Oxfordshire cluster is one of the crown jewels of our science and innovation community. The work taking place here will ensure the UK continues to blaze a trail from drug discovery and scale-up all the way through to manufacturing, ultimately delivering new therapies that will transform countless lives, while driving economic growth for the UK.”

Professor Steve Davies, Emeritus Professor at the University of Oxford and academic founder of OAI, unveiled a plaque commemorating the event. The ceremony was also attended by Elizabeth Hodgkin, daughter of British Nobel Prize winning chemist Dorothy Crowfoot Hodgkin, after whom Evotec’s campus in Abingdon is named.

Dr Werner Lanthaler, Chief Executive Officer of Evotec SE, commented: “Dorothy Crowfoot Hodgkin Campus is one of Evotec’s fastest-growing fully integrated research and development centres. Building on the early success of OAI, most notably under leadership of Dr Mario Polywka, the site has been pivotal for Evotec’s success as a whole. Mario was a founding chemist of OAI who became the company’s CEO, and subsequently served for many years as Evotec’s COO and Abingdon Site Head. We are grateful that he continues to remain a member of our Supervisory Board to this day.”

Dr Adam Stoten, SVP Academic Partnerships and Head of Evotec’s Abingdon site, commented: “Opening B95 enables us to grow further our business sustainably and we are grateful to our friends and partners who celebrated this milestone together with us today. I would like to express particular gratitude to those who built OAI’s and then Evotec’s presence on the Milton Park site.”



More news and updates 

SiSaf’s bio-courier technology enables clinical trial success for topical treatment of mild to moderate Alopecia areata

SiSaf Ltd announced that a licensee of the ProSilic® variant of its technology has reported positive topline results from a randomised, placebo-controlled, multi-dose Phase II trial evaluating its topical treatment for mild to moderate (patchy) alopecia areata.

Manchester Met opens applications for September cohort of degree apprenticeships in science and sustainability

Employers looking for new talent or to upskill their current workforce can benefit from degree apprenticeships, starting Autumn 2024.

Discovery Park partners with Canterbury Christ Church University to open CoLab

Discovery Park, Kent’s thriving life science community, has opened the doors to CoLab, a new shared lab facility. In partnership with Canterbury Christ Church University, CoLab has been specially designed for early-stage life science businesses, providing flexible bench space in a collaborative coworking environment.

New blood test could prevent sudden child deaths caused by hereditary heart condition

A new blood test that could identify children with a potentially fatal heart condition has been developed by researchers at UCL (University College London) and Great Ormond Street Hospital (GOSH), thanks to investment from the charity Action Medical Research and self-funded not-for-profit, LifeArc.

Macomics announces appointment of Simon Dew as new Chief Business Officer

Macomics Ltd, a leader in macrophage drug discovery has announced the appointment of Simon Dew in the newly created position of Chief Business Officer (CBO). He will be instrumental in advancing Macomics’ mission to develop first-in-class medicines targeting macrophage-driven diseases of high unmet medical need, in oncology and chronic inflammatory diseases.

Bruntwood SciTech launches all new life science accelerator at Alderley Park

We’re delighted to announce the launch of the life science accelerator at Alderley Park, powered by Bruntwood SciTech and funded by the UK Government through the UK Shared Prosperity Fund. This initiative is designed to support early-stage life science companies across the UK, driving innovation and economic growth in the North West.

Biomanufacturing policy summit report 2024: policy pathways for biomanufacturing in Europe

This report summarises the summit’s main discussion points and takeaways and uses them as a foundation to build a strengths, weaknesses, opportunities and threats (SWOT) analysis for biomanufacturing in Europe.

Brandon Capital announces sixth fund with $270 million initial close to drive life science innovation

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at $270 million.

RSSL opens doors to innovation for the first time with exclusive behind-the-scenes event

RSSL, for the first time, will be opening their doors to not just clients. Providing a unique opportunity to the industry to delve into the science that drives innovation and see first hand what happens behind the scenes at RSSL.

Medannex unveils first-in-human study of novel cancer therapy at ASCO 2024

Medannex Ltd (Edinburgh) today revealed details of the attainment study at the American Society of Clinical Oncology (ASCO) annual meeting. The phase 1b oncology study is the first clinical evaluation of a therapy targeting annexin-A1, a new and unique cancer target.

 

More within